These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32360890)

  • 1. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.
    Liu Y; Qiu N; Shen L; Liu Q; Zhang J; Cheng YY; Lee KH; Huang L
    J Control Release; 2020 Jul; 323():431-441. PubMed ID: 32360890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation.
    Luo K; Yang L; Yan C; Zhao Y; Li Q; Liu X; Xie L; Sun Q; Li X
    Small; 2023 Oct; 19(40):e2302834. PubMed ID: 37264710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
    Wang Z; Cordova LE; Chalasani P; Lu J
    Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
    Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
    ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
    Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
    Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death.
    Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H
    Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
    Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
    Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
    Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
    J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
    Wang G; Romero Y; Thevarajan I; Zolkiewska A
    Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
    Zhao Q; He X; Qin X; Liu Y; Jiang H; Wang J; Wu S; Zhou R; Yu C; Liu S; Zhang H; Tian M
    Front Immunol; 2022; 13():938439. PubMed ID: 35812418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
    Santana-Krímskaya SE; Franco-Molina MA; Zárate-Triviño DG; Prado-García H; Zapata-Benavides P; Torres-Del-Muro F; Rodríguez-Padilla C
    Biomed Pharmacother; 2020 Jun; 126():110062. PubMed ID: 32172064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
    Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H
    J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
    Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
    J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer.
    Yao D; Wang Y; Bian K; Zhang B; Wang D
    Biomaterials; 2023 Jan; 292():121920. PubMed ID: 36442436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
    Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC
    Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
    Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photosensitive small extracellular vesicles regulate the immune microenvironment of triple negative breast cancer.
    Ding YN; Ding HY; Li H; Yang R; Huang JY; Chen H; Wang LH; Wang YJ; Hu CM; An YL; Zhang ZY; Yu WP; Tang QS; Shao GL
    Acta Biomater; 2023 Sep; 167():534-550. PubMed ID: 37302734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.